Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
The company has raised US$4.5 million in funding for its AI operating system
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
This initiative encapsulates the essence of OPPI’s commitment towards enabling a healthier India
Subscribe To Our Newsletter & Stay Updated
